PMID- 38524576
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240326
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 6
DP  - 2024 Mar 30
TI  - Cardioprotective effect of antioxidant combination therapy: A highlight on MitoQ 
      plus alpha-lipoic acid beneficial impact on myocardial ischemia-reperfusion 
      injury in aged rats.
PG  - e28158
LID - 10.1016/j.heliyon.2024.e28158 [doi]
LID - e28158
AB  - OBJECTIVE: (s): Considering the poor prognosis of ischemic heart disease and the 
      diminished effectiveness of cardioprotective interventions in the elderly, it 
      becomes necessary to investigate the interaction of aging with protection during 
      myocardial ischemia/reperfusion injury (IRI). This study was conducted to assess 
      the impact of mitoquinone (MitoQ) and alpha-lipoic acid (ALA) preconditioning on 
      cardioprotection following IRI in aged rats. METHODS: Fifty aged male Wistar rats 
      (22-24 months old) were divided into five groups including Sham, IR, and 
      treatment groups receiving ALA and/or MitoQ. Treatment groups were received 
      100 mg/kg/day ALA by oral gavage and/or 10 mg/kg/day MitoQ by intraperitoneal 
      injection for 14 consecutive days. An in vivo model of myocardial IRI was 
      established through ligation of coronary artery for 30 min and it's reopening for 
      24 h. The left ventricles were removed at the end of reperfusion to assess 
      oxidative stress indicators, mitochondrial function, and expression of 
      mitochondrial dynamic genes. Myocardial infarct size (IS), hemodynamic 
      parameters, and serum lactate dehydrogenase (LDH) level were also measured. 
      RESULTS: Combination of MitoQ and ALA reduced oxidative stress, LDH level, and IS 
      in aged hearts subjected to IRI. It also enhanced mitochondrial function and 
      upregulated Mfn1, Mfn2, and Foxo1 and downregulated Drp1 and Fis1 gene 
      expression. Co-administration of MitoQ and ALA partially restored IRI-induced 
      hemodynamic changes to normal state. In all measured parameters, the effect of 
      combined treatment was greater than monotherapies. CONCLUSION: The combination 
      therapy of MitoQ and ALA demonstrated considerable therapeutic potential in 
      protecting the aging heart against IRI by improving oxidative stress, 
      mitochondrial function, and dynamics in aged rats.
CI  - (c) 2024 Published by Elsevier Ltd.
FAU - Oskuye, Zohreh Zavvari
AU  - Oskuye ZZ
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Iran.
AD  - Student Research Committee, Tabriz University of Medical Sciences, Iran.
AD  - Department of Physiology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Iran.
FAU - Mehri, Keyvan
AU  - Mehri K
AD  - Student Research Committee, Tabriz University of Medical Sciences, Iran.
FAU - Mokhtari, Behnaz
AU  - Mokhtari B
AD  - Department of Physiology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Iran.
AD  - Molecular Medicine Research Center, Tabriz University of Medical Sciences, Iran.
FAU - Bafadam, Soleyman
AU  - Bafadam S
AD  - Department of Physiology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Iran.
AD  - Molecular Medicine Research Center, Tabriz University of Medical Sciences, Iran.
FAU - Nemati, Samira
AU  - Nemati S
AD  - Physiology Research Center, Semnan University of Medical Sciences, Iran.
FAU - Badalzadeh, Reza
AU  - Badalzadeh R
AD  - Molecular Medicine Research Center, Tabriz University of Medical Sciences, Iran.
LA  - eng
PT  - Journal Article
DEP - 20240314
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10957437
OTO - NOTNLM
OT  - Aging
OT  - Cardioprotection
OT  - Combination therapy
OT  - Ischemia
OT  - Mitochondria
OT  - Oxidative stress
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/03/25 06:42
MHDA- 2024/03/25 06:43
PMCR- 2024/03/14
CRDT- 2024/03/25 04:27
PHST- 2023/11/12 00:00 [received]
PHST- 2024/03/12 00:00 [revised]
PHST- 2024/03/13 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2024/03/25 06:42 [pubmed]
PHST- 2024/03/25 04:27 [entrez]
PHST- 2024/03/14 00:00 [pmc-release]
AID - S2405-8440(24)04189-6 [pii]
AID - e28158 [pii]
AID - 10.1016/j.heliyon.2024.e28158 [doi]
PST - epublish
SO  - Heliyon. 2024 Mar 14;10(6):e28158. doi: 10.1016/j.heliyon.2024.e28158. 
      eCollection 2024 Mar 30.